CSPC Pharmaceutical Group (HKG:1093) has obtained marketing approval for a new indication of Omalizumab for injection, which has been developed by unit CSPC Megalith Biopharmaceutical, from China's National Medical Products Administration, a Monday bourse filing said.
The new indication, which is the second approved indication for the drug in China, is for the treatment of moderate to severe persistent allergic asthma.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.